C3 and paroxysmal nocturnal hemoglobinuria: Dual treatments can reduce the available blood plasma C3 and C5, regulating terminal functions of opsonophagocytosis and lysis, in diseases like PNH that demonstrate extra- and intra-vascular hemolysis.